Share this video  

AACR 2021 | RAMP: Phase Ib study of rucaparib & enzalutamide in mCRPC

Arpit Rao, MD, University of Minnesota, Minnesota, MN, discusses the genomic characteristics and response to rucaparib and enzalutamide in the Phase Ib RAMP study (NCT04179396) of metastatic castration-resistant prostate cancer (mCRPC). Rucaparib, a PARP inhibitor, has been approved as a monotherapy in the United States; the RAMP study aims to investigate the safety and potential drug-drug interaction between the PARP inhibitor and enzalutamide in mCRPC. In this study, the combination had an acceptable safety profile, similar to that known from the individual agents and this combination will undergo further evaluation in a Phase III clinical trial. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.